0 references
Efficacy of First-Line Treatment With Pertuzumab and Trastuzumab in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Routine Clinical Practice
World Journal of Oncology2024Vol. 15(3), pp. 454–462
Natalia Camejo, Cecilia Castillo, Dahiana Amarillo, Heber de los Santos, Gaston Samurio, Ahinara Silva-Marquez, F.E. Enriquez Sosa, Claudia Vera, R G Xavier, Guadalupe Herrera, Isabel Alonso, Gabriel Krygier
Abstract
This study demonstrates the disparity in oncological treatment efficacy between clinical trials and clinical reality in Uruguay, emphasizing the importance of authentic environment research for more representative and effective medicine in Latin America.
Related Papers
- → A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action(2020)47 cited
- → Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer(2017)18 cited
- → Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases(2021)9 cited
- → Abstract 3477: Pertuzumab in combination with trastuzumab enhanced the anti-tumor activity in HER2-positive human gastric cancers(2010)3 cited
- → Supplementary Figure 3 from Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer(2023)